Monopar Therapeutics (MNPR) News Today $34.51 -0.12 (-0.35%) Closing price 04:00 PM EasternExtended Trading$34.49 -0.02 (-0.04%) As of 05:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MNPR Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Monopar Therapeutics Inc. (NASDAQ:MNPR) Short Interest Down 13.8% in MayMonopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report) was the recipient of a significant decrease in short interest in the month of May. As of May 15th, there was short interest totalling 38,000 shares, a decrease of 13.8% from the April 30th total of 44,100 shares. Based on an average daily trading volume, of 25,800 shares, the days-to-cover ratio is currently 1.5 days. Currently, 1.0% of the company's shares are sold short.June 5, 2025 | marketbeat.comMonopar Therapeutics added to Russell 3000 and 2000 indexes, stock up 15%June 3, 2025 | msn.comMonopar Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® IndexesJune 3, 2025 | globenewswire.comMonopar Therapeutics (NASDAQ:MNPR) Stock Rating Upgraded by Wall Street ZenWall Street Zen raised shares of Monopar Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday.May 24, 2025 | marketbeat.comPoint72 Asset Management L.P. Takes Position in Monopar Therapeutics Inc. (NASDAQ:MNPR)Point72 Asset Management L.P. bought a new stake in Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 167,892 shares of the company's stock, valueMay 23, 2025 | marketbeat.comJanus Henderson Group PLC Invests $23.44 Million in Monopar Therapeutics Inc. (NASDAQ:MNPR)Janus Henderson Group PLC purchased a new stake in shares of Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 1,046,899 shares of the company's stock, vMay 18, 2025 | marketbeat.comMonopar Therapeutics Reports First Quarter 2025 Financial Results and Recent DevelopmentsMay 13, 2025 | globenewswire.comMonopar Therapeutics Presents Long-Term Efficacy and Safety Data for ALXN1840 in Wilson Disease at EASL International Liver Congress 2025May 8, 2025 | nasdaq.comMonopar Presents ALXN1840 Late-Breaker Data at EASL 2025May 7, 2025 | globenewswire.comGeode Capital Management LLC Acquires 24,530 Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR)Geode Capital Management LLC lifted its position in shares of Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) by 174.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 38,596 shares of the company's stMay 4, 2025 | marketbeat.comRA Capital Management L.P. Invests $11.25 Million in Monopar Therapeutics Inc. (NASDAQ:MNPR)RA Capital Management L.P. acquired a new stake in shares of Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 511,207 shares of the company's stock, valued at apMay 3, 2025 | marketbeat.comMonopar Therapeutics (MNPR) Projected to Post Earnings on ThursdayMonopar Therapeutics (NASDAQ:MNPR) will be releasing earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-monopar-therapeutics-inc-stock/)May 3, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Takes Position in Monopar Therapeutics Inc. (NASDAQ:MNPR)Adage Capital Partners GP L.L.C. purchased a new stake in Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 599,195 shares of the company's stock, valuApril 30, 2025 | marketbeat.comMonopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025April 29, 2025 | globenewswire.comPiper Sandler Remains a Buy on Monopar Therapeutics Inc (MNPR)April 14, 2025 | markets.businessinsider.comADAR1 Capital Management LLC Takes $2.86 Million Position in Monopar Therapeutics Inc. (NASDAQ:MNPR)ADAR1 Capital Management LLC bought a new position in Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 130,037 shares of the company's stock, valued at approxApril 9, 2025 | marketbeat.comMonopar Therapeutics Inc. (NASDAQ:MNPR) Major Shareholder Tactic Pharma Llc Sells 33,334 SharesMonopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report) major shareholder Tactic Pharma Llc sold 33,334 shares of Monopar Therapeutics stock in a transaction on Wednesday, April 2nd. The stock was sold at an average price of $35.00, for a total transaction of $1,166,690.00. Following the transaction, the insider now directly owns 822,255 shares of the company's stock, valued at $28,778,925. The trade was a 3.90 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Large shareholders that own more than 10% of a company's stock are required to disclose their transactions with the SEC.April 6, 2025 | marketbeat.comQ1 EPS Forecast for Monopar Therapeutics Lowered by AnalystMonopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) - Equities researchers at HC Wainwright reduced their Q1 2025 earnings per share estimates for shares of Monopar Therapeutics in a note issued to investors on Tuesday, April 1st. HC Wainwright analyst S. Lee now expects that the company will pApril 5, 2025 | marketbeat.comTactic Pharma Llc Sells 33,334 Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR) StockApril 5, 2025 | insidertrades.comJones Trading Reaffirms Hold Rating for Monopar Therapeutics (NASDAQ:MNPR)Jones Trading reissued a "hold" rating on shares of Monopar Therapeutics in a research report on Wednesday.April 4, 2025 | marketbeat.comMonopar Therapeutics (NASDAQ:MNPR) Posts Earnings Results, Misses Estimates By $1.87 EPSMonopar Therapeutics (NASDAQ:MNPR - Get Free Report) posted its earnings results on Monday. The company reported ($2.23) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.36) by ($1.87).April 3, 2025 | marketbeat.comHC Wainwright Has Negative Outlook of MNPR FY2029 EarningsMonopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) - Research analysts at HC Wainwright reduced their FY2029 earnings per share estimates for Monopar Therapeutics in a report released on Tuesday, April 1st. HC Wainwright analyst S. Lee now anticipates that the company will earn $3.35 per shareApril 3, 2025 | marketbeat.comMonopar Therapeutics downgraded to Hold from Buy at JonesResearchApril 2, 2025 | markets.businessinsider.comJones Trading Downgrades Monopar Therapeutics (MNPR)April 2, 2025 | msn.comJonesTrading downgrades Monopar Therapeutics Inc (MNPR) to a HoldApril 2, 2025 | markets.businessinsider.comWe Think Monopar Therapeutics (NASDAQ:MNPR) Can Easily Afford To Drive Business GrowthApril 2, 2025 | finance.yahoo.comHC Wainwright Reiterates "Buy" Rating for Monopar Therapeutics (NASDAQ:MNPR)HC Wainwright reissued a "buy" rating and issued a $40.00 price objective on shares of Monopar Therapeutics in a research note on Tuesday.April 2, 2025 | marketbeat.comMonopar Therapeutics reports Q4 EPS ($2.23) vs. (60c) last yearApril 1, 2025 | markets.businessinsider.comMonopar Therapeutics reports Q4 EPS ($2.23) vs. (60c) last yearApril 1, 2025 | markets.businessinsider.comMonopar Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent DevelopmentsMarch 31, 2025 | globenewswire.comMonopar Therapeutics' (MNPR) "Overweight" Rating Reaffirmed at Piper SandlerPiper Sandler reiterated an "overweight" rating and set a $76.00 price target on shares of Monopar Therapeutics in a research report on Wednesday.March 20, 2025 | marketbeat.comMonopar Therapeutics (MNPR) to Release Quarterly Earnings on ThursdayMonopar Therapeutics (NASDAQ:MNPR) will be releasing earnings before the market opens on Thursday, March 27, Financial Modeling Prep reports.March 20, 2025 | marketbeat.comMonopar Therapeutics assumed with an Overweight at Piper SandlerMarch 19, 2025 | markets.businessinsider.comMonopar Therapeutics Inc. (NASDAQ:MNPR) Sees Significant Growth in Short InterestMonopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report) was the target of a large increase in short interest in the month of February. As of February 28th, there was short interest totalling 51,300 shares, an increase of 57.8% from the February 13th total of 32,500 shares. Based on an average trading volume of 66,900 shares, the short-interest ratio is presently 0.8 days. Approximately 1.3% of the shares of the company are short sold.March 16, 2025 | marketbeat.comMonopar Therapeutics appoints new CFOMarch 5, 2025 | investing.comMonopar Therapeutics: Strong Data, But There Are RisksMarch 4, 2025 | seekingalpha.comMonopar Therapeutics Appoints Quan Vu as New CFOMarch 3, 2025 | tipranks.comMonopar Therapeutics Appoints Lavina Talukdar to BoardFebruary 24, 2025 | tipranks.comQ1 EPS Forecast for Monopar Therapeutics Raised by AnalystMonopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) - Analysts at Brookline Capital Management increased their Q1 2025 earnings per share estimates for Monopar Therapeutics in a research note issued to investors on Wednesday, February 5th. Brookline Capital Management analyst K. Dolliver now anFebruary 10, 2025 | marketbeat.comWhy Monopar Therapeutics Inc (MNPR) Is Skyrocketing So Far In 2025February 3, 2025 | msn.comWhat is HC Wainwright's Forecast for MNPR FY2026 Earnings?Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) - HC Wainwright lifted their FY2026 EPS estimates for Monopar Therapeutics in a note issued to investors on Wednesday, January 22nd. HC Wainwright analyst S. Lee now anticipates that the company will post earnings per share of $0.70 for the yeJanuary 24, 2025 | marketbeat.comRosalind Franklin University's Helix 51 Incubator Welcomes Monopar TherapeuticsJanuary 23, 2025 | prnewswire.comFY2029 Earnings Estimate for MNPR Issued By HC WainwrightMonopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) - Equities research analysts at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for shares of Monopar Therapeutics in a research note issued to investors on Wednesday, January 22nd. HC Wainwright analyst S. Lee anticipatesJanuary 23, 2025 | marketbeat.comMonopar Therapeutics price target raised to $40 from $22 at H.C. WainwrightJanuary 23, 2025 | finance.yahoo.comMonopar Therapeutics Gains ‘Buy’ Rating Amid Promising Licensing Deal with AstraZeneca and Strong Growth ProspectsJanuary 22, 2025 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Monopar Therapeutics Inc (MNPR), Nektar Therapeutics (NKTR)January 22, 2025 | markets.businessinsider.comHC Wainwright Forecasts Strong Price Appreciation for Monopar Therapeutics (NASDAQ:MNPR) StockHC Wainwright boosted their price target on Monopar Therapeutics from $22.00 to $40.00 and gave the company a "buy" rating in a report on Wednesday.January 22, 2025 | marketbeat.comMonopar Therapeutics files to sell 882,761 shares of common stock for holdersJanuary 16, 2025 | markets.businessinsider.comPiper Sandler Initiates Coverage of Monopar Therapeutics (MNPR) with Overweight RecommendationJanuary 10, 2025 | msn.comMonopar Therapeutics initiated with an Overweight at Piper SandlerJanuary 10, 2025 | markets.businessinsider.com Get Monopar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MNPR and its competitors with MarketBeat's FREE daily newsletter. Email Address MNPR Media Mentions By Week MNPR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MNPR News Sentiment▼0.730.68▲Average Medical News Sentiment MNPR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MNPR Articles This Week▼22▲MNPR Articles Average Week Get Monopar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MNPR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ArriVent BioPharma News Pharming Group News Immunome News Chimerix News Avid Bioservices News Gyre Therapeutics News Cogent Biosciences News Replimune Group News Cronos Group News Vir Biotechnology News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MNPR) was last updated on 6/10/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredWhy 2026 will be a disaster for many Americans2025 Market Crash The first-quarter stock crash left investors wondering what lies ahead. Today 50-year Wal...Chaikin Analytics | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monopar Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Monopar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MNPR Stock Free MNPR Stock Alerts